Quantcast
Last updated on April 19, 2014 at 5:20 EDT

Latest Orphan drugs Stories

2013-12-09 08:29:18

Filanesib demonstrated clinical activity as a single agent and in combination with proteasome inhibitors BOULDER, Colo., Dec. 9, 2013 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) announced positive data for newly named filanesib (ARRY-520) as a single agent and in combination with proteasome inhibitors (PI) in patients with multiple myeloma (MM) at the 2013 Annual Meeting of the American Society of Hematology. (Logo:...

2013-12-09 08:27:09

Initial Data Demonstrate Safety and Antileukemic Activity in Older Patients with Acute Myeloid Leukemia NEW YORK, Dec. 9, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, were presented in a poster session on Saturday, December 7, 2013 at the American Society of Hematology's (ASH) 55th Annual Meeting and...

2013-12-08 20:20:38

- ENESTnd data indicate trend for longer overall survival and event-free survival in newly diagnosed Ph+ CML patients on Tasigna versus Gleevec(1) EAST HANOVER, N.J., Dec. 8, 2013 /PRNewswire/ -- Findings from three large, randomized Phase III studies demonstrate the superiority of Tasigna(®) (nilotinib) compared to Gleevec(®) (imatinib mesylate) tablets* at achieving deeper molecular responses across various Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) patient...

2013-12-08 08:22:17

NEW ORLEANS, Dec. 8, 2013 /PRNewswire-USNewswire/ -- A series of studies presented today during the 55th American Society of Hematology Annual Meeting and Exposition in New Orleans uncover promising efficacy and safety results for several unique compounds and combination treatments, each aimed at improving long-term outcomes for patients with blood disorders ranging from clots to cancer. Recent advances have helped hematologists better understand the cellular activity of blood...

2013-12-03 16:25:12

Company to Hold Conference Call and Webcast at 9:00 am ET, Wednesday, December 4, 2013 SAN DIEGO, Dec. 3, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced a regulatory update after receiving feedback from the U.S. Food and Drug Administration (FDA) on the development of quizartinib (AC220), the Company's lead...

2013-12-02 08:30:29

Initial Data Show That Fractionated Doses of Actimab-A in Combination with LDAC are Safe and Have Antileukemic Activity in Older Patients with Acute Myeloid Leukemia NEW YORK, Dec. 2, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, reported today that data from an abstract of a study investigating the Company's...

2013-11-22 20:22:37

First and only FDA-approved treatment option for patients with this type of thyroid cancer WHIPPANY, N.J., THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Nov. 22, 2013 /PRNewswire/ -- Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq:AMGN), today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR(®) (sorafenib) tablets for the treatment of patients...

2013-11-19 08:28:41

Findings Highlight Company's Growing Hematologic Area of Focus, Including Ibrutinib, Siltuximab and Daratumumab RARITAN, N.J., Nov. 19, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced that data related to three Janssen compounds have been selected for presentation at the 55(th) American Society of Hematology (ASH) Annual Meeting in New Orleans, LA. Nine pieces of company-sponsored research will be presented out of a total of nearly 50 abstracts involving...

2013-11-18 08:27:51

Actinium Expects Single Trial Required for Regulatory Approval NEW YORK, Nov. 18, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative, targeted payload immunotherapeutics for the treatment of advanced cancers, provided a corporate update on its two most advanced clinical programs. Kaushik J. Dave Ph.D., MBA, President and Chief Executive Officer, hosted a call on November 11, 2013 to discuss...

2013-11-15 23:03:44

St. Jude Children’s Research Hospital leads study showing that a drug withdrawn from the market in 2010 may enhance the effectiveness of bone marrow transplants for select pediatric leukemia patients Memphis, Tenn. (PRWEB) November 15, 2013 Combining the drug gemtuzumab ozogamicin (GO) with conventional chemotherapy may improve the outcome of bone marrow transplantation for some children battling high-risk acute myeloid leukemia (AML), according to a study led by St. Jude Children’s...